Poly ICLC (Oncovir)

N/A

Report date: 2023/11/02 15:47:13

Base Information

Drug NamePoly ICLC (Oncovir)
Drug Alias NameP.I.C.L.C.Polyinosinic polycytidylic acidHiltonolPolyriboinosinicpolyribocytidylic acidpolyinosinic-polycytidylic acid-polylysine-carboxymethylcellulose +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionImmunomodulatorsNatural killer cells stimulantsToll like receptor 3 agonists
TargetsToll like receptor 3
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Metastatic breast cancerLow-grade Glioma +[24] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited States
CombinationsYes
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesNational Institutes Of HealthOncovir Inc
China Registration ClassN/A

Develop Information

Active CompaniesA Glimmer of Hope FoundationNational Institutes Of HealthOncovir Inc +[8] 
Inactive CompaniesNevada Cancer InstituteUniversity Of Alabama At Birmingham
Active IndicationsCoronavirus Disease 2019 (COVID-19)Metastatic breast cancerUrinary Bladder Neoplasms +[19] 
Inactive IndicationsLow-grade GliomaCarcinoma, Non-Small-Cell LungLymphoma, T-Cell +[5] 

Other Information

ATC CodeN/A
Related LinksN/A